Regenxbio Inc (NASDAQ:RGNX) — Market Cap & Net Worth
Market Cap & Net Worth: Regenxbio Inc (RGNX)
Regenxbio Inc (NASDAQ:RGNX) has a market capitalization of $526.79 Million ($526.79 Million) as of September 17, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #12012 globally and #3028 in its home market, demonstrating a -8.90% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Regenxbio Inc's stock price $7.98 by its total outstanding shares 66013192 (66.01 Million). Also see Regenxbio Inc (RGNX) total assets for a full breakdown of the balance sheet.
Regenxbio Inc Market Cap History: 2015 to 2026
Regenxbio Inc's market capitalization history from 2015 to 2026. Data shows change from $1.10 Billion to $526.79 Million (-6.74% CAGR). Also see Regenxbio Inc cash conversion from operations for how efficiently the company converts equity into cash flow.
Index Memberships
Regenxbio Inc is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.66 Trillion | 0.02% | #331 of 976 |
|
NASDAQ Composite
IXIC
|
$41.69 Trillion | 0.00% | #1200 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.88 Trillion | 0.03% | #185 of 263 |
Weight: Regenxbio Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Regenxbio Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Regenxbio Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check Regenxbio Inc stock price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
5.58x
Regenxbio Inc's market cap is 5.58 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $1.22 Billion | $4.59 Million | -$62.97 Million | 266.84x | N/A |
| 2017 | $2.19 Billion | $10.39 Million | -$73.17 Million | 211.19x | N/A |
| 2018 | $2.77 Billion | $218.50 Million | $99.94 Million | 12.67x | 27.71x |
| 2019 | $2.70 Billion | $35.23 Million | -$94.73 Million | 76.76x | N/A |
| 2020 | $2.99 Billion | $154.57 Million | -$111.25 Million | 19.37x | N/A |
| 2021 | $2.16 Billion | $470.35 Million | $127.84 Million | 4.59x | 16.89x |
| 2022 | $1.50 Billion | $112.72 Million | -$280.32 Million | 13.28x | N/A |
| 2023 | $1.18 Billion | $90.24 Million | -$263.49 Million | 13.13x | N/A |
| 2024 | $510.28 Million | $83.33 Million | -$227.10 Million | 6.12x | N/A |
| 2025 | $950.59 Million | $170.44 Million | -$193.88 Million | 5.58x | N/A |
Competitor Companies of RGNX by Market Capitalization
Companies near Regenxbio Inc in the global market cap rankings as of September 17, 2026. Review RGNX goodwill-adjusted equity ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Regenxbio Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #187 globally with a market cap of $130.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #353 globally with a market cap of $78.34 Billion USD.
- CSL Ltd (AU:CSL): Ranked #457 globally with a market cap of $59.87 Billion USD ( AU$84.62 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #505 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #187 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.09 Billion | $513.26 |
| #353 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $78.34 Billion | $774.61 |
| #457 | CSL Ltd | AU:CSL | $59.87 Billion | AU$174.41 |
| #505 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $145.62 |
Regenxbio Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, Regenxbio Inc's market cap moved from $1.10 Billion to $ 526.79 Million, with a yearly change of -6.74%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $526.79 Million | -44.58% |
| 2025 | $950.59 Million | +86.29% |
| 2024 | $510.28 Million | -56.94% |
| 2023 | $1.18 Billion | -20.86% |
| 2022 | $1.50 Billion | -30.64% |
| 2021 | $2.16 Billion | -27.91% |
| 2020 | $2.99 Billion | +10.72% |
| 2019 | $2.70 Billion | -2.34% |
| 2018 | $2.77 Billion | +26.17% |
| 2017 | $2.19 Billion | +79.25% |
| 2016 | $1.22 Billion | +11.75% |
| 2015 | $1.10 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 17th, 2026 the market cap of Regenxbio Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $526.79 Million USD |
| MoneyControl | $526.79 Million USD |
| MarketWatch | $526.79 Million USD |
| marketcap.company | $526.79 Million USD |
| Reuters | $526.79 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Regenxbio Inc
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular … Read more